Applied Dna Sciences EBIT

As of the most recent data (June 2026), APDN shows a EBIT of $-35M. That compares with $-13M in the prior-year period — down 159.5% year over year. That is below the Materials sector average of $31B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, APDN's EBIT is now $-35M (was $-13M) — a 159.5% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Applied Dna Sciences is outperforming or lagging.

The Materials sector average EBIT is about $31B. Applied Dna Sciences is at $-35M, which is lower that average. That is roughly 100.1% below the sector mean. Use the comparison chart on this page to see how APDN stacks up against individual peers as well.

Tracking APDN's ebit over time shows whether Applied Dna Sciences is scaling, shrinking, or reshaping that part of the business. The current reading is $-35M That compares with $-13M in the prior-year period — down 159.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Applied Dna Sciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-35M) with ownership activity and broader fundamentals.